Praluent® (alirocumab) injection receives fda approval to treat children with genetic form of high cholesterol

Approval extends treatment of praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (hefh) approval extends treatment of praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (hefh)
REGN Ratings Summary
REGN Quant Ranking